Anthony Aiudi

Innodem Neurosciences is committed to improving the effectiveness and quality of life and care of patients with neurological problems. Innodem works with the pharmaceutical industry, leading medical professionals, and artificial intelligence experts to develop and promote Eye Movement Biomarkers (EMBs) & Gaze Mapping Biomarkers (GMBs) as important clinical assessment tools in the field of neurology. It is building a series of disease-specific tests embodied in an intuitive App that captures EMB & GMB data. The vision is that over time, while leveraging the latest advances in machine and deep learning, this EMB/GMB platform will assist users to accurately diagnose and monitor neurological disorders affecting eye-movements or cognition such as multiple sclerosis, Alzheirmer’s, Parkinson’s or related disorders, Frontotemporal dementia, Cancer-related cognitive impairment (Chemo Brain) and many others.

A team of pediatricians in your pocket! 👩🏽‍⚕️👨🏼‍⚕️🧑🏻‍⚕️ ⌚️ Save time 💵 Save money 🩺 Great care 👇 Learn more

AdvanCell is a clinical stage radiopharmaceutical company developing an innovative pipeline of 212Pb-based Targeted Alpha Therapies for cancer patients. AdvanCell’s platform technology addresses the most significant challenge in Targeted Alpha Therapy – the reliable and scalable supply of isotope. AdvanCell’s novel drug discovery, preclinical processes, and state-of-the-art facilities leverage daily access to 212Pb, the ideal isotope for Targeted Alpha Therapy. For more information, please visit www.advancell.com.au

i2o Therapeutics is Boston-based company developing next generation biologic therapies

We are redefining digestive health by pioneering non-endoscopic diagnostics, enabling early detection of diseases and access to care for everyone, everywhere.

Neutrolis, Inc. is a biotechnology company developing therapeutics that target neutrophils, the most abundant immune cell in our body. Neutrolis’ lead program targets Neutrophil Extracellular Traps (NETs). NETs are a fundamental arm of the innate immune system and play an important role in chronic and acute diseases. Based in Cambridge, MA, Neutrolis was founded by two of the earliest and most cited leaders in the NETs field and supported by seasoned business leaders.

Revolutionizing The Treatment of Severe Allergic Reactions and Anaphylaxis Anaphylaxis, also called allergic or anaphylactic shock, is a sudden, severe and life-threatening allergic reaction. Biothea is focused on revolutionizing the treatment of severe allergic reactions and anaphylaxis by providing needle-free, convenient, and cost-effective alternative to currently available products. Copyright © 2021 Biothea Pharma, Inc - All

Founded in 1986 by the Chan family, Morningside is a technology and life science venture investment firm. With offices in Boston, Shanghai and London, the firm invests globally. The group is managed by investment professionals who are entrepreneurial, have deep industry knowledge and are effective in the local environment in which they operate. In addition to its investment activities, Morningside Ventures is strongly committed to social responsibility.

Innodem Neurosciences is committed to improving the effectiveness and quality of life and care of patients with neurological problems. Innodem works with the pharmaceutical industry, leading medical professionals, and artificial intelligence experts to develop and promote Eye Movement Biomarkers (EMBs) & Gaze Mapping Biomarkers (GMBs) as important clinical assessment tools in the field of neurology. It is building a series of disease-specific tests embodied in an intuitive App that captures EMB & GMB data. The vision is that over time, while leveraging the latest advances in machine and deep learning, this EMB/GMB platform will assist users to accurately diagnose and monitor neurological disorders affecting eye-movements or cognition such as multiple sclerosis, Alzheirmer’s, Parkinson’s or related disorders, Frontotemporal dementia, Cancer-related cognitive impairment (Chemo Brain) and many others.

A team of pediatricians in your pocket! 👩🏽‍⚕️👨🏼‍⚕️🧑🏻‍⚕️ ⌚️ Save time 💵 Save money 🩺 Great care 👇 Learn more

AdvanCell is a clinical stage radiopharmaceutical company developing an innovative pipeline of 212Pb-based Targeted Alpha Therapies for cancer patients. AdvanCell’s platform technology addresses the most significant challenge in Targeted Alpha Therapy – the reliable and scalable supply of isotope. AdvanCell’s novel drug discovery, preclinical processes, and state-of-the-art facilities leverage daily access to 212Pb, the ideal isotope for Targeted Alpha Therapy. For more information, please visit www.advancell.com.au

i2o Therapeutics is Boston-based company developing next generation biologic therapies

We are redefining digestive health by pioneering non-endoscopic diagnostics, enabling early detection of diseases and access to care for everyone, everywhere.